Keep Kratom Legal in Kansas - Thu, 15 Feb 2018 00:00:00 EST

Petition by the National Kratom Coalition. This petition is in response to the approved Senate Bill 282 that would list mitragynine and 7-hydroxymitragynine as Schedule 1 controlled substances. Both compounds are found in a natural-growing plant commonly called kratom. A ban on kratom will have an immediate and detrimental impact on the health of thousands of Kansas citizens who have chosen kratom as an all-natural, safer alternative to the prescription drugs they would otherwise be forced to take for their medical conditions. It is my belief that scheduling kratom will result in the deaths of many Kansans whose medical conditions are properly controlled by the use of kratom. Making kratom a Schedule 1 narcotic would force many of these people back onto prescription drugs that may not be effective for them. Many others will refuse to return to those drugs because of the side effects, addiction potential, and long-term health effects that come with their use. They will exchange those conditions for chronic pain, and many other terrible afflictions. Still others who have used kratom as an effective treatment for addiction to heroin, alcohol or prescription opioids will likely relapse and return to those drugs. The consequences of this will also spike the numbers of deaths related to suicide and overdose. That is an outcome that can be diverted, as kratom does not pose a significant threat to the health of the public. Click HERE to sign! ,
The American Kratom Association (AKA) is speaking out on the heels of the U.S. Food and Drug Administration’s (FDA) February 6, 2018 announcement that its latest research suggests that kratom (mitragyna speciosa) is, in fact, an opioid. But a group of scientists have issued a letter to Acting DEA Administrator Robert Patterson and Presidential advisor Kellyanne Conway, urging them to disregard the FDA’s latest batch of information. The nine scientists wrote, in part, “We believe strongly that the current body of credible research on the actual effects of kratom demonstrates that it is not dangerously addictive, nor is it similar to ‘narcotics like opioids’ with respect to ‘addiction’ and ‘death,’ as stated by the FDA in its November 14th Kratom Advisory. “Equally important, four surveys indicate that kratom is presently serving as a lifeline away from strong, often dangerous opioids for many of the several million Americans who use kratom. A ban on kratom that would be imposed by CSA Scheduling would put them at risk of relapse to opioid use with the potential consequence of overdose death.” AKA Board Chairman Dave Herman also came down on the FDA and its PHASE Modeling System, stating that, “The FDA wants the DEA (U.S. Drug Enforcement Administration) to accept the ‘novel scientific analysis and computational model’ theory that if kratom ‘binds’ to the opioid receptor in the brain just as opioids do, then it logically must have the same respiratory suppressing effect on users as opioids do, ergo, kratom must be an opioid.” He added, “The problem is that their conclusion is completely and utterly wrong!...It smells of desperation because they know they are losing the battle of real science, so they made up ‘novel’ new science.” Researchers and the scientific community as a whole agree that kratom appears to impact the brain’s µ-opioid receptors or MORs. The FDA ran kratom through its proprietary PHASE modeling system in order to arrive at this conclusion. But opponents such as the AKA point out that µ-opioid receptors activation is not the only criteria for defining and identifying an opiate. One must also examine the substance’s effects, amongst other properties. In fact, AKA Board Chairman Herman highlighted this fact in a very adept manner in his formal written response to the FDA’s announcement. Herman pointed out that there are other non-opioid substances—such as naloxone (sold under the brand name Narcan)—have the ability to bind to and activate the brain’s µ-opioid receptors. But critically, naloxone is not considered an opiate. Approved by the FDA in 1971, naloxone is included on the World Health Organization’s (WHO) List of Essential Medicines and it is widely regarded as one of the safest and most effective medications in existence. Naloxone does have the ability to bind to MORs, but it lacks other key properties of an opiate, such as the tendency to induce respiratory suppression. It’s an opiate’s respiratory suppression properties that make this type of substance so potentially dangerous. Naloxone is routinely used worldwide to treat patients who are suffering from acute opioid overdose. In fact, naloxone is credited with saving thousands upon thousands of overdose patients who would otherwise succumb to respiratory failure. High doses of opioid drugs can depress respiratory function to the point whereby the patient ceases to breathe, ultimately resulting in death. But naloxone reverses the opiate’s effects by acting upon the very same receptors in the brain. “The ‘novel scientific analysis and computational model’ would be stumped to explain why naloxone is not dangerous but kratom is because both substances bind to the opioid receptors in the brain,” Herman explained, adding, “Kratom does bind to the opioid receptors in the brain, but it does not suppress a user’s respiratory system any more than naloxone does. That is why there are no deaths that can be classified as ‘caused’ by use of kratom….But the FDA claims that the new data produced by their ‘whiz-bang’ new computer model ‘provides even stronger evidence of kratom compounds’ opioid properties.’” In fact, Herman points out that kratom “...does not suppress a user’s respiratory system any more than naloxone does. That is why there are no deaths that can be classified as ‘caused’ by use of kratom.” The FDA went on to cite a total of 44 deaths that were allegedly “associated with the use of kratom.” But In the AKA’s formal response to the FDA’s announcement, Herman wrote, “...the FDA admitted that ‘many of the cases reported could not be fully assessed because of the limited information provided.’ The FDA is not claiming that there are 44 deaths caused by kratom use. They are claiming that 44 people died from a range of causes—including just being completely unexplainable (sic)—while also using kratom. Those people who died likely also drank water, a soda, or used hair shampoo in the shower that day.” Yet none of those other substances were formally “associated” with the deaths. Notably, the FDA has never successfully banned a substance because it supposedly held the power to be dangerous when mixed with another substance. But that’s precisely what kratom proponents say is happening here. Herman explained, “The FDA properly gives guidance on the contraindications of using drugs and other substances concurrently. But it does not ban one substance because it might create a death if used concurrently with another substance...the FDA makes the huge leap to conclude that kratom is not ‘just a plant—it’s an opioid.’ He called upon the FDA to keep the American public’s best interests in mind, urging the agency to rely upon solid, scientific research and not hype, conjecture, or computer-generated “trick plays.” Herman also urged the DEA to ignore what he categorized as the FDA’s latest attempt to get kratom scheduled as a controlled substance. Kratom captured the attention of the FDA back in 2009, when it made headlines in Sweden where a total of nine people died in connection with a mix of drugs called Krypton. Krypton contained kratom and what was found to be a toxic dose of o-desmethyltramadol. O-desmethyltramadol is the active metabolite found in tramadol, a commonly-prescribed pain medication. In fact, the o-desmethyltramadol dosage was officially cited as the cause of death in those cases. “The FDA is well aware of the true cause of death—based on [research performed by] highly credentialed scientists—was from that active metabolite of tramadol,” Herman added. Notably, the DEA had previously considered an emergency scheduling that would have placed kratom’s key alkaloids—mitragynine and 7-hydroxymitagynine—in the same category as highly dangerous drugs such as heroin and cocaine. While that emergency Schedule 1 status did not ultimately proceed, the future of kratom remains uncertain in the U.S. A number of U.S. states have already banned kratom, including Wisconsin, Indiana, Vermont, Rhode Island, Washington D.C., Tennessee, Alabama, Arkansas and a handful of additional counties in states such as Florida and Illinois. But the proposed emergency scheduling did have one positive impact: it prompted thousands of Americans to come forward and share their personal anecdotes to depict precisely how kratom has improved their quality of life. The American Kratom Association is a non-profit organization that is committed to sharing these stories on their website, ,
Kratom continues to come under fire, most recently with the U.S. Food and Drug Administration (FDA) issuing a kratom “advisory.” With such an uncertain future, it’s now more important than ever before for kratom enthusiasts to speak out in support of mitragyna speciosa! The American Kratom Association (AKA) has drafted an open letter to acting U.S. Drug Enforcement Administration (DEA) Director Robert W. Patterson, urging the agency to conduct its own 8-factor analysis of kratom and its properties. The study would “test the credibility of the scheduling recommendation submitted by the U.S. Food and Drug Administration.” Click here to read and sign the AKA’s open letter. Why is the AKA Promoting an Independent 8-Factor Kratom Study? Kratom proponents argue that an objective scientific study will make it clear that kratom is a safe botanical; one that holds great potential for use as a treatment for a wide variety of ailments and conditions. Enthusiasts often point out that this botanical that has been used for generations by native Southeast Asian cultures to treat everything from insomnia and anxiety, to pain, lethargy, and depression. This stands in sharp contrast to the FDA’s claims that suggest kratom is a “gateway drug ” or substitute for opioids. “In its enactment of the Controlled Substances Act, Congress has wisely required the DEA to do its own independent review on scheduling recommendations submitted by the FDA to provide a second opinion on important substance scheduling issues. That second opinion is desperately needed in the evaluation of kratom because the science directly refutes the FDA claims,” the AKA’s open letter states. The AKA and countless kratom enthusiasts are calling for this independent analysis due to what they believe is a woefully inaccurate representation by the FDA. For instance, the FDA suggested that kratom has “narcotic opioid-like” potential for abuse. It was also stated that the substance is primarily used to “get high.” But heaps of scientific evidence and thousands of personal anecdotes suggest that kratom is, in fact, a rather poor opioid substitute—particularly for anyone who is seeking a high. This is just one contradiction that has thousands of kratom consumers concerned. Notably, the DEA has already been supplied with an independent 8-factor kratom analysis performed by Jack Henningfield, Ph.D. Henningfield is regarded as one of the nation’s leading experts on issues surrounding substance abuse, addiction and substance safety. The AKA is also encouraging the DEA Director to consider four additional studies that “clearly demonstrate the harm that will be done by any scheduling order on kratom.” As many recall, the DEA previously sought an “emergency” scheduling for kratom which would have placed the plant in the same category as heroin and cocaine. This led to tremendous outcry amongst kratom enthusiasts, who came out in droves to sign petitions, write letters and—most importantly—share their personal experiences with kratom. Thousands came forward to detail how kratom had positively impacted their lives. Ultimately, the emergency scheduling was halted. How Can You Help Keep Kratom Legal? But kratom’s legal status still remains uncertain. Several states have already banned kratom, including Alabama, Arkansas, Indiana, Rhode Island, Tennessee, Vermont, and Wisconsin. What’s more, the FDA is actively detaining many kratom shipments to the U.S., which is clearly a concern for those who favor and support the sale of kratom. For this reason, we encourage you to take a few minutes to sign and share the American Kratom Association’s open letter to DEA Director Robert W. Patterson. Click here to read the letter. You can also make a difference by writing to local and federal lawmakers. Share your positive experiences with kratom and how it has transformed your life. Also, encourage legislators to support an additional scientific investigation into kratom and its effects. Many believe that this hard scientific evidence is the key to maintaining kratom’s legal status. Click here to learn more about contacting congressmen and senators. ,
The U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb, M.D., has issued a kratom advisory on what he calls the “deadly risks associated with kratom.” Although just hours following the release, the American Kratom Association (AKA) formally filed a demand calling upon the FDA to “rescind” the statement. The AKA has made this demand on the grounds that the advisory is reportedly “misleading and unsubstantiated,” with “discredited, incomplete, and mischaracterized scientific claims,” according to a press release issued by the advocacy group. What Did the FDA's Kratom Advisory Say? At its core, the FDA advisory on kratom sought to issue a “public health advisory related to mounting concerns regarding risk associated with the use of kratom,” as the agency cited concerns over “harmful unapproved products that have been crossing our borders in increasing numbers.” In a move that has been highly criticized by the AKA and other kratom advocacy groups, the FDA Commissioner said that “we must ask ourselves whether the use of kratom – for recreation, pain or other reasons – could expand the opioid epidemic.” To support this remark, Dr. Gottlieb cited several facts, such as a ten-fold increase in call volume to the U.S. Poison Control Centers concerning kratom. But some are criticizing the Commissioner for his failure to mention the fact that many of these calls involved other substances that could have been responsible for adverse effects. What's more, kratom proponents have noted that the increased call volume to the Poison Control Center could easily be explained by the medical community's lack of familiarity with kratom, combined with its rise in popularity in the U.S. If a patient presents with symptoms, it's routine to ask about any and all substances they've ingested or been exposed to. In cases where a physician is unfamiliar with a substance and how it could relate to the patient's symptoms or any treatments that may be administered, it's common practice to consult the U.S. Poison Control Center. This agency maintains up-to-date information on thousands of compounds, including new and/or uncommon substances. But advocates argue that a call to the Poison Control Center does not necessarily prove causation; it only suggests that the patient may have contacted a specific substance around the time that a medical situation arose. One pro-kratom nurse took to social media to write, “The reality is that the U.S. Poison Control Center is simply a resource for accurate information on various drugs, chemicals, substances and compounds. Let's say you arrive in the ER with a broken leg and if you admit you've ingested kratom recently, but the physician does not know how kratom may impact emergency surgery and the medications that will be used during that procedure. That physician is going to call Poison Control to learn more. If we buy into the FDA's advisory, then this is a red mark against kratom, despite the fact that the substance in no way caused the fracture. That feels misleading.” But the FDA Commissioner presented a unified view on kratom, reiterating that “...the FDA has evidence to show that there are significant safety issues associated with [kratom's] use. Before it can be legally marketed for therapeutic uses in the U.S., kratom’s risks and benefits must be evaluated as part of the regulatory process for drugs that Congress has entrusted the FDA with....We believe using the FDA’s proven drug review process would provide for a much- needed discussion among all stakeholders.” And on that last point, many kratom proponents agree. Advocates argue that a formal, thorough, and objective review of kratom's properties would almost certainly lead to FDA approval in some capacity. It's a point that the AKA drives home in its formal statement in response to the FDA's kratom advisory: “...several points in the FDA advisory are at odds with the facts and these are facts that FDA staff have at their disposal and should have acknowledged. For example, contrary to the statement that kratom has 'narcotic opioid like' abuse potential and other effects, kratom is primarily used for benefit by millions of Americans and not to get 'high.' In fact, kratom is a poor substitute for opioids for getting high.” Kratom, Its Legal Status and the FDA A member of the coffee plant family, kratom (mitragyna speciosa) is derived from the dried leaves of the kratom plant, which is native to southeast Asian nations such as Malaysia, Thailand and Indonesia. Kratom is favored for a number of uses, ranging from incense to aromatherapy and beyond. Notably, the FDA has not approved kratom for use as a supplement, food product, or medication. But this has not stopped many individuals from brewing kratom tea and filling capsules with kratom powder for ingestion. At one point, the FDA even attempted to implement an emergency kratom ban that would place kratom in the same category as cocaine and heroin, but tremendous public outcry prevailed and the agency ultimately backed off. The proposed ban did have a couple benefits in the eyes of kratom advocates. That event raised public awareness and it also prompted kratom enthusiasts to share countless anecdotal cases with the media and the world as a whole. Countless individuals have claimed that kratom transformed their life after they used it as a natural alternative to opiate painkillers, while others claimed they've used kratom to ease opiate withdrawal symptoms. Notably, the FDA advisory indicated that the agency has been involved in numerous recent seizures at the border: “To fulfill our public health obligations, we have identified kratom products on two import alerts and we are working to actively prevent shipments of kratom from entering the U.S. At international mail facilities, the FDA has detained hundreds of shipments of kratom. We’ve used our authority to conduct seizures and to oversee the voluntary destruction of kratom products...” These seizures could result in an imbalance as demand outpaces supply, although no serious shortages have been reported as of mid-November 2017. Currently, though, kratom is legal to obtain, sell, and possess in most regions of the United States and beyond. Kratom bans have been enacted in Arkansas, Tennessee, Alabama, Wisconsin, and Indiana. Several nations have also banned kratom, including Australia, Thailand, Germany, Malaysia, and Sweden. Notably, this recent FDA advisory has not resulted in any changes to kratom’s legal status. The kratom advisory concludes by saying, “To those who believe in the proposed medicinal uses of kratom, I encourage you to conduct the research that will help us better understand kratom’s risk and benefit profile, so that well studied and potentially beneficial products can be considered. In the meantime...the FDA will continue to take action on these products in order to protect public health.” ,

The History of Kratom - Tue, 3 Oct 2017 00:00:00 EST

A native plant to southeast Asia, kratom (Mitragyna Speciosa) can be found growing wildly across Thailand, Indonesia, Malaysia, and Borneo. It has been harvested for centuries for it’s its, mood elevation, calming and stimulating properties. Kratom is still a natural solution many seek out today, as a component in their holistic health toolbox.The Background of KratomKratom has been used for thousands of years by local villagers for therapeutic reasons, but it didn’t gain attention outside of southeast Asia until the early 1880s when it was discovered and documented by botanist, Pieter Willem Korthals. Traditionally, kratom has been used by Thai peasants, laborers, and farmers. It’s illegal in two of its native regions, Thailand and Malaysia. There are many kratom users worldwide who voice strong opinions over ending the criminalization of kratom, and ending the corrupt political ties to its illegalization that favored the booming opium trade of the past century. Today, Kratom is legal in most U.S. states.The Kratom Plant and Its VarietiesKratom, a part of the Rubiaceae coffee tree family, comes in four primary species that originate in different regions in southeast Asia, and provide varying effects:· Bali—Gives a more relaxing effect at higher doses, and can be stimulating when taken in low doses.· Thai—The longest lasting and strongest of the varieties. It’s said to be calming.· Malaysia—Almost identical to Balinese kratom. You may hear the term “ketum” used to describe kratom from Malaysia.· Maeng Da—Maeng Da kratom translates to “pimp grade” kratom and originates from Thailand. It’s the strongest kratom strain available and is used for its energizing effects. Kratom strains are further categorized by “vein:” · Red Vein—Longer lasting, and more relaxing and less stimulating than other strains· Green Vein—Energizing and uplifting· White Vein—Energizing and euphoric Choosing the Best Kratom from a Quality SupplierThe key to choosing the best kratom supplier is finding a quality source that chooses their kratom from the finest sources grown organically in its native region. Look for a supplier that carries multiple strains to offer you all of the mood-boosting, energizing, and calming effects you need to feel your best. *Disclaimer: All products on the website are not for human consumption, and are for aromatherapy and research purposes only. ,